Please note that this product (marketed as Vitrakvi) was withdrawn from the Community Register of designated orphan medicinal products in July 2019 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.
On 21 March 2018, orphan designation (EU/3/18/1995) was granted by the European Commission to Loxo Oncology Limited, United Kingdom, for larotrectinib for the treatment of salivary gland cancer.
The sponsorship was transferred to Bayer AG - Germany, in June 2018.
|Disease / condition||
Treatment of salivary gland cancer
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.